Treatment of endocrine pancreatic tumors

References

• Wilder RM, Allan FN, Power MH, Robertson HE. Carcinoma of the islands of the pancreas. Hyperinsulinism and hypoglycemia. J Am Med Assoc 1927; 89: 348–55
   Google Scholar
• Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142: 709–28
   PubMed Web of Science ®Google Scholar
• Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet 1974; 2: 1–5
   PubMed Web of Science ®Google Scholar
• Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958; 25: 374–80
   PubMed Web of Science ®Google Scholar
• Ganda OP, Weir GC, Soeldner JS, et al. Somatostatinoma”: a somatostatin containing tumor of the endocrine pancreas. N Engl J Med 1977; 296: 963–7
   PubMed Web of Science ®Google Scholar
• Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986; 315: 1–5
   PubMed Web of Science ®Google Scholar
• Imura H. Ectopic hormone syndromes. Clin Endocrinol Metab 1980; 9: 235–60
   PubMedGoogle Scholar
• Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol 1999; 10: 170–6
   PubMedGoogle Scholar
• Corbetta S, Peracchi M, Cappiello V, et al. Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: Identification of one pancreatic ghrelinoma. J Clin Endocrinol Metab 2003; 88: 3117–20
   PubMed Web of Science ®Google Scholar
• Eriksson B, Arnberg H, Lindgren PG, et al. Neuroendocrine tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990; 228: 103–13
   PubMed Web of Science ®Google Scholar
• Rindi G, Capella C, Solcia. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med 1998; 76: 413–20
   PubMedGoogle Scholar
• Eriksson B, Arnberg H, Oberg K, et al. Chromogranins–new sensitive markers for neuroendocrine tumors. Acta Oncol 1989; 28: 325–9
   PubMed Web of Science ®Google Scholar
• Schurmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg 1992; 16: 697–701
   PubMedGoogle Scholar
• Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004; 43: 617–25
   PubMed Web of Science ®Google Scholar
• Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol 2004; 43: 626–36
   PubMedGoogle Scholar
• Welbourn, RB,Wood, SM,Polak, JM,Bloom, SR, . In:. Pancreatic endocrine tumors.SR Bloom,Polak, JR, , editors., Gut Hormones, 2nd edition., London, Churchill Livingstone; 1981. p., 547–1554
   Google Scholar
• Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112: 1024–31
   PubMedGoogle Scholar
• Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36–42
   PubMed Web of Science ®Google Scholar
• Montenegro F, Lawrence GD, Macon W, Pass C. Metastatic glucagonoma: improvement after surgical debulking. Am J Surg 1980; 139: 424–7
   PubMedGoogle Scholar
• Nagorney DM, Blood SR, Polak JM, Blumgart LH. Resolution of recurrent Verner-Morrison syndrome by resection of metastatic vipoma. Surgery 1983; 93: 348–53
   PubMedGoogle Scholar
• Wiedenmann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998; 22: 309–18
   PubMed Web of Science ®Google Scholar
• Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 2002; 132: 976–82
   PubMedGoogle Scholar
• Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extra-hepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study. Surgery 2003; 133: 375–82
   PubMed Web of Science ®Google Scholar
• Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138: 859–66
   PubMedGoogle Scholar
• Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet carcinomas of the pancreas; a twenty-year experience. Surgery 1988; 104: 1011–7
   PubMed Web of Science ®Google Scholar
• Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078–85
   PubMedGoogle Scholar
• Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002; 26: 1052–6
   PubMed Web of Science ®Google Scholar
• Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26: 985–90
   PubMed Web of Science ®Google Scholar
• Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997; 225: 347–54
   PubMed Web of Science ®Google Scholar
• Lang H, Schlitt HJ, Schmidt H, et al. Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas-a single center experience with ten patients. Langenbecks Arch Surg 1999; 384: 370–7
   PubMedGoogle Scholar
• Fernandez JA, Robles R, Marin C, et al. Role of liver transplantation in the management of metastatic neuroendocrine tumors. Transplant Proc 2003; 5: 1832–3
   Google Scholar
• Ackerman NB, Sien WM, Silverman NA. The blood supply of experimental liver metastases. 3. The effects of acute ligation of hepatic artery or portal vein. Surgery 1972; 71: 636–41
   PubMed Web of Science ®Google Scholar
• Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumor metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988; 108: 340–4
   PubMed Web of Science ®Google Scholar
• Carrasco CH, Chuang V, Wallace S. Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 1983; 149: 79–83
   PubMed Web of Science ®Google Scholar
• Weiss RB. Streptozotocin: A review of its pharmacology, efficacy and toxicity. Cancer Treat Rep 1982; 66: 427–38
   PubMedGoogle Scholar
• Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79: 108–18
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lavin P, Hahn G. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1982; 66: 1567–9
   PubMedGoogle Scholar
• Altimari A, Badrinath K, Reisel HJ, Printz RA. DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery 1987; 102: 1009–17
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared to streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189–94
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz M, Hahn RG, Klaassen D. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519–23
   PubMed Web of Science ®Google Scholar
• Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990; 65: 1883–90
   PubMed Web of Science ®Google Scholar
• Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32: 203–8
   PubMed Web of Science ®Google Scholar
• Moertel CG, Kvols LK, O′Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in anaplastic variants of these neoplasma. Cancer 1991; 68: 227–32
   PubMed Web of Science ®Google Scholar
• Fjällskog M-L, Granberg D, Welin S, et al. Treatment with cisplatin and etoposid in patients with neuroendocrine tumors. Cancer 2001; 92: 1101–7
   PubMed Web of Science ®Google Scholar
• Isaac A, Lindenmann J. Virus interference. I. The interferon. By A Isaacs and J Lindenmann, 1957. J Interferon Res 1987; 7: 429–38
   Google Scholar
• Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K. Effects of interferon on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 1990; 50: 3413–15
   PubMed Web of Science ®Google Scholar
• Grandér D, Öberg K, Lundqvist M-L, Janson ET, Eriksson B, Einhorn S. Interferon-induced enhancement of 2′-5′-oligoadenylat synthetase in mid-gut carcinoid tumors. Lancet 1990; 336: 337–40
   PubMed Web of Science ®Google Scholar
• Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129–33
   PubMed Web of Science ®Google Scholar
• Eriksson B, Oberg K, Alm G, et al. Treatment of malignant endocrine pancreatic tumors with human leucocyte interferon. Lancet 1986; 2: 1307–9
   PubMed Web of Science ®Google Scholar
• Ronnblom LE, Alm GV, Oberg K. Autoimmun phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991; 30: 537–40
   PubMed Web of Science ®Google Scholar
• Öberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon-alfa-2b: development of neutralizing antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531–5
   PubMed Web of Science ®Google Scholar
• Merimsky O, Chaitchik S. Neurotoxicity of interferon-alpha. Anticancer drugs 1992; 3: 567–70
   PubMedGoogle Scholar
• Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–9
   PubMed Web of Science ®Google Scholar
• Reichlin, S. Somatostatin. Part 1 and 2.N Engl J Med. 1983;309:1495–1501, and 1556–63.
   Google Scholar
• Chen C, Vincent JD, Clarke IJ. Ion channels and the signal transduction pathways in the regulation of growth hormone secretion. Trends Endocrinol Metab 1994; 5: 227–33
   PubMedGoogle Scholar
• Buscail L, Delesque N, Èsteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of proliferation by somatostatin analogues: mediation by human somatostatin receptors ssTR1 and ssTR2. Proc Natl Acad Sci USA 1994; 91: 2315–9
   PubMed Web of Science ®Google Scholar
• Buscail L, Estéve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptors subtypes ssTR2 and ssTR5 through different mechanisms. Proc Natl Acad Sci USA 1995; 92: 1580–4
   PubMed Web of Science ®Google Scholar
• Sharma K, Patel YC, Srikant CB. Subtype-elective induction of wild-type p53 and apoptosis, but not cell-cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688–96
   PubMed Web of Science ®Google Scholar
• Teijeiro R, Rios R, Costoya JA. Activation of somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 2002; 12: 31–8
   PubMed Web of Science ®Google Scholar
• Reubi JC, Hacki WH, Lamberts SW. Hormone producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 1987; 65: 1127–34
   PubMed Web of Science ®Google Scholar
• Long RG, Barnes AJ, Adrian TE, et al. Suppression of pancreatic endocrine tumor secretion by long-acting somatostatin analogue. Lancet 1979; 2: 764–7
   PubMed Web of Science ®Google Scholar
• Arnold R, Trautmann ME, creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic gastroenteropancreatic tumors. Gut 1996; 38: 430–8
   PubMed Web of Science ®Google Scholar
• Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8: 1041–4
   PubMed Web of Science ®Google Scholar
• Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid tumors and malignant islet cell tumors. Cancer 1997; 79: 830–4
   PubMed Web of Science ®Google Scholar
• Tiensuu Janson EM, Ahlström H, Andersson T, Oberg K. Octreotide and interferon-alfa: a new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992; 28: 1647–50
   Google Scholar
• Fjällskog M-L, Sundin A, Westlin J-E, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs. Med Oncol 2002; 19: 35–42
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, et al. International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy for metastatic neuroendocrine gastroenteropancreatic tumors. The international lanreotide and interferon alfa study. J Clin Oncol 2003; 21: 2689–96
   PubMed Web of Science ®Google Scholar
• Krenning E, Kooij P, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionucleide therapy. Digestion 1996; 57(Suppl 1)57–61
   PubMed Web of Science ®Google Scholar
• Tiensuu Janson E, Eriksson B, Oberg K, et al. Treatment with high dose [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors- evaluation of therapeutic and toxic effects. Acta Oncol 1999; 38: 373–7
   PubMed Web of Science ®Google Scholar
• Anthony L, Woltering W, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-penterotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32: 123–32
   PubMed Web of Science ®Google Scholar
• Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002; 43: 610–6
   PubMed Web of Science ®Google Scholar
• Kwekkeboom D, Bakker W, Kooij PP, et al. 177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28: 1319–25
   PubMedGoogle Scholar
• Kwekkeboom D, Bakker B, Kam BL, et al. Treatment of patients with gastroenteropancreatic (GEP) tumors with a novel radiolabelled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med 2003; 30: 417–22
   Google Scholar
• Cavallo–Perin P, Bruno A, Ozzello A, et al. Comparison of acute and subacute effects of deflazacort and prednisone on glucose metabolism in man. Eur J Pharmacol 1984; 26: 357–62
   Google Scholar
• Grant DB, Dunger DB, Burns EC. Long–term treatment with diazoxid in childhood hyperinsulinism. Acta Endocrinol Suppl 1986; 279: 340–5
   PubMedGoogle Scholar
• Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE. Treatment of inoperable glucagonomas with the long-acting somatostatin analogue SMS 201-995. N Engl J Med 1986; 314: 1686–9
   PubMed Web of Science ®Google Scholar
• Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythemas in the glucagonomas syndrome. Clin Endocrinol 2002; 57: 827–31
   PubMed Web of Science ®Google Scholar
• Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent results cancer res 1996; 142: 193–207
   PubMedGoogle Scholar
• Yamashiro Y, Yamamoto K, Sato M. Loperamide therapy in a child with vipoma-associated diarrhea. Lancet 1982; 1: 1413
   PubMedGoogle Scholar
• Ewe K. Opium drops in diarrhea caused by Crohn disease. Dtsch Med Wochenschr 1997; 122: 174–5
   PubMedGoogle Scholar
• Engelhardt D, Jacob K, Doerr HG. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome. Klin Wochenschr 1989; 67: 241–7
   PubMedGoogle Scholar
• Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin endocrinol 1991; 35: 169–78
   PubMed Web of Science ®Google Scholar
• Iser G, Pfohl M, Dorr U, Weiss EM, Seif FJ. Ectopic ACTH secretion due to a bronchopulmonary carcinoid localized by somatostatin receptor scintigraphy. Clin Invest 1994; 72: 887–91
   PubMedGoogle Scholar
• Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282: 737–40
   PubMed Web of Science ®Google Scholar
• Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction?. Int J Cancer 1994; 56: 681–8
   PubMed Web of Science ®Google Scholar
• Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1-5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20: 59–67
   PubMedGoogle Scholar
• Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 1999; 13: 647–55
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–6
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi C, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–45
   PubMed Web of Science ®Google Scholar
• Ferry D, Hammond L, Ransom M, et al. Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000; 19: abs 5E
   Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052–6
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloic leukaemia. N Engl J Med 2001; 344: 1031–7
   PubMed Web of Science ®Google Scholar
• Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase receptor inhibitor, in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000; 19: abs 686
   Google Scholar
• Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003; 9: 1469–73
   PubMed Web of Science ®Google Scholar
• Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumors. Targeting the epidermal growth factor receptor gefitinib (ZD1839). Br J Cancer 2003; 89: 1766–75
   PubMed Web of Science ®Google Scholar
• McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091–6
   PubMed Web of Science ®Google Scholar